logo-loader
CytoDyn

CytoDyn takes major step forward filing trial protocol for HIV Monotherapy

CytoDyn (OTCQB:CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive Investors Vancouver on Skype to bring news the company has filed to the FDA,  the pivotal trial protocol for leronlimab as a monotherapy for HIV patients. 

Pourhassan also shared details about the work involved to get to this point and what the next stage is.

Quick facts: CytoDyn

Price: $0.42

Market: OTCQB
Market Cap: $153.19 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn named herein, including the promotion by the Company of CytoDyn in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech's HIV monotherapy dose escalating trial with its flagship drug leronlimab (PRO 140) topped expectations. Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate. 

1 week, 1 day ago

2 min read